Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Codeine price, strengths & recalls

Pharmacies pay $22.37 for 30 tablets of Codeine 30 mg tablet this week, and from $20.31 to $37.50 across its 3 priced strengths and forms. 2 manufacturers make it. 3 recalls are ongoing. Its official label last changed on December 31, 2025.

3 open recallsGeneric
Pharmacies pay$22.37for 30 tablets of 30 mg tablet+2.7% in 4 weeks
Fair cash price
$36.23
Strengths
3
Makers
2
Updated
Nov 11

Codeine price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
15 mg tablet$0.6770$20.31 / 30 tablets-0.1%-1.1%
30 mg tablet$0.7458$22.37 / 30 tablets+2.7%+12.6%
60 mg tablet$1.25$37.50 / 30 tablets-2.3%+20.0%

The lowest cost per tablet is 15 mg tablet at $0.6770. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
3 ongoing recalls14 recalls on record, latest Jun 7, 2023

Recalls

Showing the 6 most relevant of 14 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for codeine? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedDecember 31, 2025
Version25 of 9
EffectiveDec 22, 2025
Read the label

These highlights do not include all the information needed to use CODEINE SULFATE TABLETS safely and effectively. See full prescribing information for CODEINE SULFATE TABLETS.CODEINE SULFATE tablets, for oral use CIIInitial U.S. Approval: 1950

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF CODEINE SULFATE TABLETS

Addiction, Abuse, and Misuse

Because the use of Codeine Sulfate Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1), Dosage and Administration (2.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Codeine Sulfate Tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Codeine Sulfate Tablets are essential [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of Codeine Sulfate Tablets, especially by children, can result in a fatal overdose of codeine [see Warnings and Precautions (5.2)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Codeine Sulfate Tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. [see Warnings and Precautions (5.4)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].

Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children

Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism [see Warnings and Precautions (5.6)]. Codeine Sulfate Tablets are contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications (4)]. Avoid the use of Codeine Sulfate Tablets in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with Codeine Sulfate Tablets requires careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. [See Warnings and Precautions (5.7), Drug Interactions (7)].

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF CODEINE SULFATE TABLETS

See full prescribing information for complete boxed warning.

•

Codeine Sulfate Tablets exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.1)

•

Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Codeine Sulfate Tablets are essential. (5.2)

•

Accidental ingestion of Codeine Sulfate Tablets, especially by children, can result in a fatal overdose of codeine. (5.2)

•

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)

•

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)

•

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)

•

Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. (5.6) Codeine Sulfate Tablets are contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (4). Avoid the use of Codeine Sulfate Tablets in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.

•

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with Codeine Sulfate Tablets requires careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (5.7, 7)

Recent major changes (as listed on the label)

Boxed Warning

|

12/2025

|

Indications and Usage (1)

|

12/2025

|

Dosage and Administration (2.2, 2.5)

|

12/2025

|

Warnings and Precautions (5.1, 5.2, 5.3, 5.14, 5.16)

|

12/2025

|

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA022402 · Hikma
First approved
July 16, 2009 (17 years ago)
Latest approved change
June 18, 2026
Approved label
PDF, Jan 5, 2026
Generic makers
1 approved generic application on the market

Codeine questions

How much does codeine cost without insurance?

Pharmacies pay about $22.37 for 30 tablets of codeine 30 mg tablet ($0.7458 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $36.23. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is codeine in shortage?

No shortage is reported for codeine right now. We check the national shortage list every day.

Has codeine been recalled?

14 recalls on record, 3 ongoing. Recalls name specific lots - check yours.

When did the codeine label last change?

The official label was last updated on December 31, 2025 (version 25). See what changed.

Talk about codeine

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.